MIT’s Center for Biomedical Innovation’s 2013 Seminar Series

An Academic and Industry Collaborative Initiative on Preventing Adventitious Agent Contaminations in Biomanufacturing

James C. Leung, PhD
Lead Investigator of the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB)
Center for Biomedical Innovation
Massachusetts Institute of Technology

Wednesday, April 17, 2013
3:00 PM, refreshments at 2:45PM
E25-401

Abstract
An industry consortium, the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) has been formed under the auspices of MIT’s Center for Biomedical Innovation. The mission of the CAACB is to pool and to share knowledge, experience and practices in the area of adventitious agent contamination in biomanufacturing. The Consortium is providing a safe and collaborative environment for networking and information exchange focused on identifying best industry practices in contamination response, corrective and preventive actions, and promoting the development of new technologies to detect adventitious agents and mitigate risk of contamination. Eighteen companies have now joined and support the Consortium as either Full Members (biomanufacturers) or Associate Members (companies supporting biomanufacturers). The inaugural project now in progress is the confidential collection and analysis of industry-wide viral contamination data with an emphasis on “lessons learned”. Specifically, the project seeks to identify industry risks as well as effective barriers to those risks. Progress on this project and future directions of the Consortium will be described.

Speaker Bio
Dr. Leung is the Academic Director of the Professional Science Master (PSM) Biotechnology Programs at Northeastern University. He also participates in projects of biotherapeutic development and manufacturing as advisor or consultant in pharmaceutical & biotechnology companies and other research organizations. With the Center of Biomedical Innovation (CBI) at MIT, he serves as the lead investigator for the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB), and the key advisor to the Biomanufacturing Research (BioMAN) program. Before his current roles, Dr. Leung worked in the biotechnology industry mainly in the areas of process development, manufacturing and product development of recombinant biotherapeutics. The companies he held full-time positions include Genentech, Inc., Repligen Corp. and Ipsen. Dr. Leung received a B.Sc. degree from the Chemical Engineering Department at MIT. For graduate studies, he received a M.Sc. degree and a Ph.D. degree in Biochemical Engineering from MIT.

Please contact Danielle Camp (dcamp@mit.edu) with questions or to RSVP